LAVA Therapeutics (NASDAQ:LVTX) Position Increased by Pathway Financial Advisors LLC

Pathway Financial Advisors LLC increased its stake in LAVA Therapeutics (NASDAQ:LVTX) by 70.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 102,500 shares of the company’s stock after purchasing an additional 42,500 shares during the period. Pathway Financial Advisors LLC owned 0.40% of LAVA Therapeutics worth $170,000 at the end of the most recent reporting period.

Separately, XTX Topco Ltd bought a new stake in LAVA Therapeutics during the 2nd quarter valued at $55,000.

LAVA Therapeutics Price Performance

NASDAQ LVTX opened at $1.64 on Wednesday. The stock has a market capitalization of $41.57 million, a P/E ratio of -1.52 and a beta of 0.51. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.39 and a current ratio of 6.39. The business’s fifty day moving average is $1.75 and its two-hundred day moving average is $2.25. LAVA Therapeutics has a 1 year low of $1.13 and a 1 year high of $6.47.

LAVA Therapeutics (NASDAQ:LVTX) last released its earnings results on Tuesday, August 20th. The company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.05. LAVA Therapeutics had a negative net margin of 228.02% and a negative return on equity of 48.53%. On average, research analysts forecast that LAVA Therapeutics will post -1.28 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

LVTX has been the topic of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $6.00 target price on shares of LAVA Therapeutics in a research note on Friday, June 28th. JMP Securities reaffirmed a “market outperform” rating and set a $6.00 target price on shares of LAVA Therapeutics in a research note on Wednesday, August 21st.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.